TITLE

SCIOS LICENSES NATRECOR TO GLAXOSIMTHKLINE IN EUROPE

PUB. DATE
February 2002
SOURCE
Worldwide Biotech;Feb2002, Vol. 14 Issue 2, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the agreement between GlaxoSmithKline Plc and Scios Inc. to license Natrecor, a drug used for treating acute heart failure.
ACCESSION #
6395337

 

Related Articles

  • Scios Inc.  // Pharmaceutical Executive;Dec97 Special Issue, Vol. 17, p90 

    Profiles Mountain View, California-based Scios Inc. Internet address; Number of employees; Company description; Markets served; Major services; Comarketing partners.

  • Natrecor fails, stock plummets. Agrawal, Alka // Nature Biotechnology;Jun99, Vol. 17 Issue 6, p520 

    Reports on the decision of the U.S. Food and Drug Administration not to approve the drug Natrecor nesiritide developed by Mountain View, California-based company Scios Inc. for the treatment of acute congestive heart failure. Reason behind the disapproval; Decrease in share price of Scios due...

  • GOOD CLINICAL TRIAL RESULTS WITH ORAL P38 KINASE INHIBITOR.  // Biotech Business;Jun2001, Vol. 14 Issue 6, p2 

    Reports that SCIO-469, a novel oral p38 kinase inhibitor developed by Scios Inc. was well-tolerated in volunteers according to results of its PhaseIb clinical trial.

  • SCIOS TO BEGIN PHASE IB MULTI-DOSE TRIAL OF SCIO-469.  // Biotech Business;Mar2001, Vol. 14 Issue 3, p2 

    Reports that Scios Inc. will begin a Phase Ib multi-dose clinical trial of its SCIO-469, an oral p38 kinase inhibitor, in the first quarter of 2001.

  • Chiron and Scios In $25 Million Deal.  // Chemical Market Reporter;11/08/99, Vol. 256 Issue 19, p22 

    Focuses on the patent and licensing agreement signed by Chiron Corp. with Scios Inc. Terms of the agreement; Licensing fees to be paid by Chiron for Scios.

  • Life science briefs.  // Chemical Market Reporter;08/31/98, Vol. 254 Issue 9, p13 

    Presents news items related to pharmaceuticals developed by different companies. US Food and Drug Administration approval for Alpharma Inc.'s combination drug for coccidiosis; Federal Trade Commission permission for Bayer AG and Scios Inc. to commercialize Scios' Natrecor; South Korean Food and...

  • The Long Road Home. Sellers, L.J. // Pharmaceutical Executive;Sep2001, Vol. 21 Issue 9, p108 

    Highlights the role of Chief Executive Officer Richard Brewer in the success of pharmaceutical company Scios. Background on the company; Changes instituted by Brewer in the company; Results of the company's clinical trial for Natrecor among congestive health failure patients; Overview of...

  • Protecting Employees During a Proxy Fight.  // Mergers & Acquisitions: The Dealermaker's Journal;Mar2000, Vol. 35 Issue 3, p15 

    Reports on the poison pill program used by Sunnyvale, California-based biopharmaceuticals company, Scios Inc. to protect its employees from the takeover plans of Third Security LLC. Compensations that will be received by employees under the protection program; Reasons for Third Security's...

  • J & J to buy Scios, adding arthritis drug. Arnold, Matthew // Medical Marketing & Media;Mar2003, Vol. 38 Issue 3, p10 

    Reports on the acquisition of Scios Inc. by Johnson & Johnson. Purchase price; Development of treatment for cardiovascular and inflammatory diseases; Creation of an oral rheumatoid arthritis drug.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics